(Q27853151)

13 November 2016

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

S Moulder

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

T Helgason

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

F Janku

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

J Wheler

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

J Moroney

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

D Booser

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

C Albarracin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

P K Morrow

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

J Atkins

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

K Koenig

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M Gilcrease

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

R Kurzrock

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

15 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

1346-1352

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

Metaplastic carcinoma of the breast: a clinicopathological review

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Biphasic metaplastic sarcomatoid carcinoma of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV163

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

21 January 2018

1 reference

12 December 2020

Metaplastic breast cancer: prognosis and response to systemic therapy

1 reference

12 December 2020

Metaplastic breast carcinoma with squamous differentiation: molecular and clinical analysis of six cases

1 reference

12 December 2020

PIK3CA mutations in advanced cancers: characteristics and outcomes

1 reference

12 December 2020

Metaplastic breast carcinoma: pathology and clinical outcome.

1 reference

12 December 2020

Identifiers

DOI

10.1093/ANNONC/MDV163

2 references

Consolidated OpenCitations Corpus – April 2017

1877596

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1877596

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25878190%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

PubMed publication ID

25878190

2 references

Consolidated OpenCitations Corpus – April 2017

1877596